Keyphrases
Adenoma
9%
Aramchol
10%
Bile
100%
Bile Acids
16%
Bile Salts
15%
Cannabis
24%
Cholecystectomy
12%
Cholesterol
55%
Cholesterol Crystallization
45%
Cholesterol Crystals
12%
Cholesterol Gallstones
18%
Chronic Hepatitis C
15%
Chronic Liver Disease
20%
Colon
9%
Colonoscopy
17%
Crohn's Disease
32%
Cryptogenic Cirrhosis
11%
Crystallization
15%
Disease Activity
11%
Duodenal Ulcer
10%
Endoscopic Retrograde Cholangiopancreatography
18%
Enzyme-linked Immunosorbent Assay (ELISA)
10%
Fatty Acid Bile Acid Conjugate
43%
Fatty Acids
10%
Fatty Liver
12%
Gallbladder
22%
Gallstones
29%
Helicobacter Pylori (H. pylori)
25%
Helicobacter Pylori Infection
9%
Human Bile
20%
Inflammation
12%
Inflammatory Bowel Disease
49%
Interferon-α (IFN-α)
12%
Israel
18%
Lecithin
10%
Liver Disease
11%
Non-alcoholic Fatty Liver Disease (NAFLD)
16%
Nucleate
18%
Omeprazole
13%
Oral Administration
15%
Phospholipids
17%
Placebo
12%
Polyps
13%
Primary Biliary Cirrhosis
13%
Primary Sclerosing Cholangitis
17%
Randomized Controlled Trial
10%
Risk Factors
11%
Telomere
9%
Triple Therapy
19%
Ulcerative Colitis
18%
Medicine and Dentistry
Adenoma
13%
Aminolevulinic Acid
7%
Bile
61%
Bile Acid Conjugate
22%
Bile Duct
11%
Bile Duct Stone
9%
Cannabis
25%
Cholecystectomy
13%
Cholelithiasis
9%
Cholesterol Stone
12%
Chronic Liver Disease
10%
Colon
11%
Colon Carcinoma
6%
Colonoscopy
22%
Colorectal Carcinoma
7%
Combination Therapy
7%
Common Bile Duct
10%
Common Bile Duct Stone
11%
Crohn's Disease
8%
Disease Activity
11%
Diseases
20%
Endoscopic Retrograde Cholangiopancreatography
21%
Endoscopic Sphincterotomy
8%
Endoscopy
11%
Enema
6%
Fatty Acid
27%
Fatty Liver
10%
Fibrosis
6%
Gallstone
26%
Helicobacter Pylori
13%
Inflammatory Bowel Disease
15%
Liver Cirrhosis
8%
Malignant Neoplasm
10%
Nonalcoholic Fatty Liver
8%
Omeprazole
6%
Oral Drug Administration
7%
Patient with Crohn's Disease
7%
Patient with Inflammatory Bowel Disease
8%
Patient with Ulcerative Colitis
7%
Phospholipid
7%
Photochemotherapy
10%
Placebo
13%
Plummer-Vinson Syndrome
7%
Polyp
15%
Polypeptide
8%
Primary Biliary Cirrhosis
6%
Primary Sclerosing Cholangitis
10%
Randomized Controlled Trial
6%
Side Effect
8%
Ulcerative Colitis
11%
Pharmacology, Toxicology and Pharmaceutical Science
Adenoma
10%
Bile Acid
15%
Bile Acid Conjugate
44%
Bile Salt
8%
Cannabidiol
9%
Cannabinoid
5%
Cannabis
30%
Chemotherapy
5%
Cholelithiasis
14%
Cholesterol Stone
14%
Chronic Hepatitis C
13%
Chronic Liver Disease
10%
Clarithromycin
6%
Clinical Trial
5%
Colorectal Carcinoma
8%
Combination Therapy
5%
Crohn's Disease
26%
Crystallization
13%
Cytotoxicity
6%
Disease Activity
9%
Diseases
20%
Duodenum Ulcer
8%
Enzyme-Linked Immunosorbent Assay
5%
Fatty Acid
45%
Fatty Liver
19%
Gallstone
26%
Helicobacter Pylori
17%
Infection
6%
Inflammation
5%
Inflammatory Bowel Disease
19%
Interferon
5%
Liver Disease
5%
Nonalcoholic Fatty Liver
8%
Nucleation
6%
Omeprazole
10%
Phospholipid
5%
Placebo
23%
Placebo-Controlled Study
5%
Polyp
15%
Polypeptide
5%
Prevalence
7%
Primary Biliary Cirrhosis
6%
Pseudomembranous Colitis
6%
Randomized Controlled Trial
10%
Remission
11%
Side Effect
13%
Tinidazole
6%
Ulcerative Colitis
20%
Ursodeoxycholic Acid
7%
